Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach in management of Anemia of Chronic Kidney Disease
Anemia is a well-developed discipline where the concepts of precision medicine have, in part and being studied extensively. This review discusses the treatment of EPO-deficient anemia and resistance in Chronic Kidney Disease (CKD). Traditionally, erythropoietin-stimulating agents (ESA) and iron supplementation have been used to manage anemia in CKD. However, these treatments have potential risks, including cardiovascular and thromboembolic events. Newer treatments have emerged to address these risks, such as slow-release and low-dosage intravenous iron, oral iron, and erythropoietin-iron combination therapy. Another novel approach is using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI). This review highlights the need for precision medicine targeting genetic components of EPO-deficient anemia in CKD and discusses individual variability of genes such as the erythropoietin gene (EPO), Interleukin-β gene (IL-β), and hypoxia-inducible factor gene (HIF). Pharmacogenomics testing aims to provide targeted therapies and interventions that are tailored to the specific characteristics of an individual, optimizing treatment outcomes and minimizing resistance and adverse effects. The article concludes by suggesting the potential of receptor modification to revolutionize treatment outcome of erythropoietin deficiency anemia through integration of the mentioned approach..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Preprints.org - (2023) vom: 14. Aug. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yugavathy, Nava [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.20944/preprints202306.1893.v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
preprintsorg040043096 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | preprintsorg040043096 | ||
| 003 | DE-627 | ||
| 005 | 20231205144750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230629s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.20944/preprints202306.1893.v1 |2 doi | |
| 024 | 7 | |a 10.20944/preprints202306.1893.v1 |2 doi | |
| 035 | |a (DE-627)preprintsorg040043096 | ||
| 035 | |a (preprintsorg)10.20944/preprints202306.1893 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yugavathy, Nava |e verfasserin |0 (orcid)0000-0001-6109-2867 |4 aut | |
| 245 | 1 | 0 | |a Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach in management of Anemia of Chronic Kidney Disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Anemia is a well-developed discipline where the concepts of precision medicine have, in part and being studied extensively. This review discusses the treatment of EPO-deficient anemia and resistance in Chronic Kidney Disease (CKD). Traditionally, erythropoietin-stimulating agents (ESA) and iron supplementation have been used to manage anemia in CKD. However, these treatments have potential risks, including cardiovascular and thromboembolic events. Newer treatments have emerged to address these risks, such as slow-release and low-dosage intravenous iron, oral iron, and erythropoietin-iron combination therapy. Another novel approach is using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI). This review highlights the need for precision medicine targeting genetic components of EPO-deficient anemia in CKD and discusses individual variability of genes such as the erythropoietin gene (EPO), Interleukin-β gene (IL-β), and hypoxia-inducible factor gene (HIF). Pharmacogenomics testing aims to provide targeted therapies and interventions that are tailored to the specific characteristics of an individual, optimizing treatment outcomes and minimizing resistance and adverse effects. The article concludes by suggesting the potential of receptor modification to revolutionize treatment outcome of erythropoietin deficiency anemia through integration of the mentioned approach. | ||
| 700 | 1 | |a Abdullah, Bashar Mudhaffar |4 aut | |
| 700 | 1 | |a Lim, Soo Kun |0 (orcid)0000-0001-7589-5150 |4 aut | |
| 700 | 1 | |a Abdul Gafor, Abdul Halim Bin |0 (orcid)0000-0003-3950-2844 |4 aut | |
| 700 | 1 | |a Wong, Muh Geot |4 aut | |
| 700 | 1 | |a Bavanandan, Sunita |4 aut | |
| 700 | 1 | |a Wong, Hin Seng |0 (orcid)0000-0002-4807-7053 |4 aut | |
| 700 | 1 | |a Huri, Hasniza Zaman |0 (orcid)0000-0002-6423-8515 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Preprints.org |g (2023) vom: 14. Aug. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:08 |
| 856 | 4 | 0 | |u https://doi.org/10.3390/cimb45080413 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.20944/preprints202306.1893.v1 |z kostenfrei |3 Volltext |
| 912 | |a preprintsorg | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 08 | ||